The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | CAR-Tography: longitudinal mapping of CAR-T toxicities across B-cell malignancies
Kai Rejeski, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, shares insights into CAR-Tography, a large international study that mapped CAR-T toxicities across B-cell malignancies, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hematotoxicity, and infections. By analyzing data from approximately 900 patients and 32,000 unique patient days, they derived a cumulative toxicity index (CTI) to describe early CAR T-cell toxicity. Three clusters were identified: high-tox, mid-tox, and low-tox, which were prognostically relevant and biologically distinct. This study provides a holistic view of CAR-T toxicity and has implications for product selection and patient stratification. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
